{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:04:12Z","timestamp":1793343852708,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011535.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000}}],"reference-count":635,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011535.pub7","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T14:30:30Z","timestamp":1754490630000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-5270","authenticated-orcid":false,"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Department of Dermatology; AP-HP H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Clinical Investigation Centre; AP-HP H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaimani","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Centre of Research in Epidemiology and Statistics (CRESS), INSERM, F-75004; Paris France"},{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Guelimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology; AP-HP H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chen","family":"Tai","sequence":"additional","affiliation":[{"name":"Medical Library, Department of Medical Education; Linkou Chang Gung Memorial Hospital; Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Beytout","sequence":"additional","affiliation":[{"name":"Department of Dermatology; AP-HP H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherry","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine; University College London, Hospitals NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Mubuanga Nkusu","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ollivier","sequence":"additional","affiliation":[{"name":"Department of Dermatology; AP-HP H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Samaran","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"},{"name":"Department of Dermatology; Montpellier University Hospital and Montpellier University; Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Hughes","sequence":"additional","affiliation":[{"name":"c\/o Cochrane Skin Group; The University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivem","family":"Afach","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Le Cleach","sequence":"additional","affiliation":[{"name":"Department of Dermatology; AP-HP H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) \u2013 EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"19","key":"10.1002\/14651858.CD011535.pub7-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"E2526","DOI":"10.3390\/ijms18122526","article-title":"The genetic basis of psoriasis","volume":"18","author":"Capon","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jid.2021.02.764","article-title":"New frontiers in psoriatic disease research, part I: genetics, environmental triggers, immunology, pathophysiology, and precision medicine","volume":"141","author":"Yan","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.jid.2021.02.743","article-title":"New frontiers in psoriatic disease research, part II: comorbidities and targeted therapies","volume":"141","author":"Yan","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"9583","key":"10.1002\/14651858.CD011535.pub7-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","article-title":"Classification and diagnostic criteria for psoriatic arthritis","volume":"64","author":"Helliwell","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","article-title":"Prevalence of joint disease in patients with psoriasis: implications for therapy","volume":"4","author":"Zachariae","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.143.9.1113","article-title":"Clinical severity of psoriasis in last 20 years of PUVA study","volume":"143","author":"Nijsten","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clindermatol.2009.03.001","article-title":"Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clinics in Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How good are clinical severity and outcome measures for psoriasis? : quantitative evaluation in a systematic review","volume":"130","author":"Spuls","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD011535.pub7-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD011535.pub7-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000109358","article-title":"Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials","volume":"216","author":"Le Cleach","year":"2008","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005028.pub3","article-title":"Topical treatments for chronic plaque psoriasis","author":"Mason","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010497.pub2","article-title":"Oral fumaric acid esters for psoriasis","author":"Atwan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3 Pt 2","key":"10.1002\/14651858.CD011535.pub7-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25","author":"Maza","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study","volume":"26","author":"Christophers","year":"1992","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudie","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2011.03993.x","article-title":"Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review","volume":"2","author":"Sbidian","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.14500","article-title":"Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies","volume":"175","author":"Balak","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"9843","key":"10.1002\/14651858.CD011535.pub7-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"9993","key":"10.1002\/14651858.CD011535.pub7-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD011535.pub7-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ddr.21263","article-title":"Small molecules in the treatment of psoriasis","volume":"76","author":"Torres","year":"2015","journal-title":"Drug Development Research"},{"issue":"17","key":"10.1002\/14651858.CD011535.pub7-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy Sheridan","year":"2022","journal-title":"Drugs"},{"issue":"21","key":"10.1002\/14651858.CD011535.pub7-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9271","key":"10.1002\/14651858.CD011535.pub7-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2015","journal-title":"Experimental Dermatology"},{"issue":"13","key":"10.1002\/14651858.CD011535.pub7-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD011535.pub7-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10284","key":"10.1002\/14651858.CD011535.pub7-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"ljae062","DOI":"10.1093\/bjd\/ljae062","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, phase III study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis","volume":"-","author":"Cai","year":"2024","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1568010043343903","article-title":"Targeting tumor necrosis factor-alpha in the therapy of psoriasis","volume":"3","author":"Gisondi","year":"2004","journal-title":"Current Drug Targets. Inflammation and Allergy"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14712598.2017.1283401","article-title":"Certolizumab pegol for the treatment of psoriasis","volume":"17","author":"Campanati","year":"2017","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0051|cit51","first-page":"123","article-title":"New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors","volume":"99","author":"Dong","year":"2017","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","article-title":"Ustekinumab in the treatment of psoriasis and psoriatic arthritis","volume":"2","author":"Savage","year":"2015","journal-title":"Rheumatology and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis","author":"Sbidian","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0058|cit58","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version February 2021 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/jamadermatol.2018.1165","article-title":"Identifying a core domain set to assess psoriasis in clinical trials","volume":"154","author":"Callis","year":"2018","journal-title":"JAMA Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clinical and Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamadermatol.2023.5439","article-title":"Patient-reported outcome measures for health-related quality of life in patients with psoriasis: a systematic review","volume":"160","author":"P\u00e9rez-Chada","year":"2024","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0064|cit64","unstructured":"Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode Available from community.cochrane.org\/review-production\/production-resources\/living-systematic-reviews#guidance"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0065|cit65","unstructured":"Covidence Veritas Health Innovation 2021"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0066|cit66","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0069|cit69","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies (last updated August 2022). In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0070|cit70","unstructured":"Current version of RoB 2 Available at https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/current-version-of-rob-2"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/eb-2017-102753","article-title":"Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article","volume":"20","author":"Chaimani","year":"2017","journal-title":"Evidence-based Mental Health"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jclinepi.2018.02.009","article-title":"Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?","volume":"100","author":"Veroniki","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","article-title":"The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes","volume":"76","author":"Veroniki","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/eb-2014-101900","article-title":"Addressing missing outcome data in meta-analysis","volume":"17","author":"Mavridis","year":"2014","journal-title":"Evidence-based Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ije\/dyt074","article-title":"Effects of study precision and risk of bias in networks of interventions: a network meta-epidemiological study","volume":"42","author":"Chaimani","year":"2013","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"S0895","key":"10.1002\/14651858.CD011535.pub7-BIB0079|cit79","first-page":"30775","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"16","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"7-8","key":"10.1002\/14651858.CD011535.pub7-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0083|cit83","unstructured":"R: A language and environment for statistical computing R Foundation for Statistical Computing 2024"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"Journal of Statistical Software"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0085|cit85","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0086|cit86","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS One"},{"issue":"21","key":"10.1002\/14651858.CD011535.pub7-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"26","key":"10.1002\/14651858.CD011535.pub7-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression","volume":"41","author":"Evrenoglou","year":"2022","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjd.19244","article-title":"Meta-analysis results do not reflect the real safety of biologics in psoriasis","volume":"184","author":"Afach","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0092|cit92","unstructured":"CINeMA: Confidence in Network Meta-Analysis Institute of Social and Preventive Medicine, University of Bern 2017"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLOS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0300060514539280","article-title":"Serum concentrations of interleukin-2 and tumour necrosis factor-alpha under cyclosporine versus acitretin treatment in plaque-type psoriasis","volume":"42","author":"Akcali","year":"2014","journal-title":"Journal of International Medical Research"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/ijd.12444","article-title":"Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis","volume":"53","author":"Al-Hamamy","year":"2014","journal-title":"International Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2006.01.004","article-title":"Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study","volume":"54","author":"Asawanonda","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0097|cit97","first-page":"1933","article-title":"Effectiveness of methotrexate and apremilast in the management of moderate to severe plaque psoriasis: a comparative study","volume":"15","author":"Ashwani","year":"2023","journal-title":"Indian Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2003.307","article-title":"Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis","volume":"48","author":"Gottlieb","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mjd.2003.10","article-title":"Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris","volume":"48","author":"Gottlieb","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1742-7843.2005.pto960318.x","article-title":"Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis","volume":"96","author":"Chladek","year":"2005","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.5455\/njppp.2023.13.04171202312052023","article-title":"The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: a randomized, double-blind, and comparative study","volume":"13","author":"Das","year":"2023","journal-title":"National Journal of Physiology, Pharmacy and Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","article-title":"Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study","volume":"37","author":"Dogra","year":"2012","journal-title":"Clinical and Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"146 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0104|cit104","first-page":"136","article-title":"Cyclosporin in psoriasis. A long-term randomized study on 37 patients","volume":"69","author":"Dubertret","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-2133.2008.08564.x","article-title":"Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial","volume":"158","author":"Gisondi","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4274\/turkderm.54771","article-title":"A single-blind study comparing acitretin and narrow-band UVB with the combination of placebo and narrow-band UVB in the treatment of plaque-type psoriasis","volume":"49","author":"Gurel","year":"2015","journal-title":"T\u00fcrkderm"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1440-0960.1963.tb01685.x","article-title":"Methotrexate in the treatment of psoriasis: a controlled clinical trial","volume":"7","author":"Hunter","year":"1963","journal-title":"Australasian Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"e006283","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor \u2013 a antagonism or cyclosporine in psoriasis","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circulation. Cardiovascular Imaging"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0110|cit110","first-page":"688","article-title":"Greater improvement of coronary artery function, left ventricular deformation and twisting by treatment with IL-17A antagonist compared to cyclosporine in psoriasis","volume":"38","author":"Ikonomidis","year":"2017","journal-title":"European Heart Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011535.pub7-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"iii341","DOI":"10.1093\/ehjci\/jex298","article-title":"Treatment with IL-17A antagonist results in a greater improvement of coronary artery function, left ventricular deformation and twisting than cyclosporine in psoriasis","volume":"18","author":"Ikonomidis","year":"2017","journal-title":"European Heart Journal \u2013 Cardiovascular Imaging"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.66344\/jpad.v34i1.2749","article-title":"Comparison of efficacy of apremilast versus methotrexate in patients with moderate to severe chronic plaque psoriasis","volume":"34","author":"Khalid","year":"2024","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"S6","key":"10.1002\/14651858.CD011535.pub7-BIB0113|cit113","first-page":"73","article-title":"Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis","volume":"30","author":"Khattri","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0114|cit114","first-page":"33","article-title":"Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis","volume":"11","author":"Khattri","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1468-3083.2009.03486.x","article-title":"Methotrexate\/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis \u2013 a randomized single-blinded placebo-controlled study","volume":"24","author":"Mahajan","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"e38802","DOI":"10.7759\/cureus.38802","article-title":"Apremilast or methotrexate: the arrows in the quiver for psoriasis","volume":"15","author":"Panda","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"350","DOI":"10.33887\/rjpbcs\/2024.15.2.62","article-title":"Comparative study of efficacy of methotrexate and apremilast in the treatment of moderate to severe plaque psoriasis","volume":"15","author":"Prathap","year":"2024","journal-title":"Research Journal of Pharmaceutical, Biological and Chemical Sciences"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0118|cit118","first-page":"453","article-title":"Efficacy of concomitant use of PUVA and methotrexate in disease clearance time in plaque type psoriasis","volume":"54","author":"Shehzad","year":"2004","journal-title":"Journal of the Pakistan Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"214","DOI":"10.25259\/IJDVL_613_19","article-title":"Safety and efficacy of methotrexate (0.3 mg\/kg\/week) versus a combination of methotrexate (0.15 mg\/kg\/week) with cyclosporine (2.5 mg\/kg\/day) in chronic plaque psoriasis: a randomised non-blinded controlled trial","volume":"87","author":"Singh","year":"2021","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000448135","article-title":"Combination therapy of etanercept and fumarates versus etanercept monotherapy in psoriasis: a randomized exploratory study","volume":"232","author":"Bezooijen","year":"2016","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0122|cit122","unstructured":"Vascular inflammation in psoriasis-ustekinumab (VIP-U) https:\/\/clinicaltrials.gov\/show\/nct02187172"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1097\/CM9.0000000000002873","article-title":"Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: a 12-week randomized placebo-controlled phase III trial with long-term extension","volume":"137","author":"Yu","year":"2024","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0124|cit124","unstructured":"A phase III study to evaluate tildrakizumab in the treatment of Chinese subjects with moderate to severe plaque type psoriasis https:\/\/clinicaltrials.gov\/show\/NCT05108766"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-008-9233-0","article-title":"Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial","volume":"29","author":"Caproni","year":"2009","journal-title":"Journal of Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0126|cit126","first-page":"188","article-title":"Long-term cyclosporin A for psoriasis","volume":"3","author":"Engst","year":"1994","journal-title":"Acta Dermatovenerologica Alpina, Panonica et Adriatica"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD011535.pub7-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0190-9622(88)70086-9","article-title":"Acitretin improves psoriasis in a dose-dependent fashion","volume":"18","author":"Goldfarb","year":"1988","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(89)70138-9","article-title":"Side-effect profile of acitretin therapy in psoriasis","volume":"20","author":"Gupta","year":"1989","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD011535.pub7-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0190-9622(89)70236-X","article-title":"A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis","volume":"21","author":"Olsen","year":"1989","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"15","key":"10.1002\/14651858.CD011535.pub7-BIB0130|cit130","first-page":"231517","article-title":"An open-labelled randomised comparative evaluation of therapeutic efficacy and safety of apremilast versus methotrexate in the treatment of patients with chronic plaque psoriasis","volume":"23","author":"Rathipriyadharshini","year":"2020","journal-title":"Annals of Tropical Medicine and Public Health"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0131|cit131","unstructured":"A study to assess the effects of apremilast and methotrexate in the treatment of patients with psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2019\/01\/017362"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0132|cit132","first-page":"5068","article-title":"The effects of acitretin on patients with psoriasis vulgaris","volume":"13","author":"Ye","year":"2020","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0133|cit133","first-page":"204","article-title":"Re-PUVA therapy for psoriasis vulgaris: an effective choice","volume":"12","author":"Y\u0131lmaz","year":"2002","journal-title":"T\u00fcrkiye Klinikleri Dermatoloji Dergisi"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011535.pub7-BIB0134|cit134","first-page":"258","article-title":"Re-PUVA therapy for psoriasis vulgaris: an effective choice","volume":"16","author":"Yilmaz","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2019.05.042","article-title":"Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis","volume":"73","author":"Yu","year":"2019","journal-title":"International Immunopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0137|cit137","first-page":"A301","article-title":"Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab","volume":"5","author":"Blauvelt","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0138|cit138","unstructured":"Study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (GP2017) and Humira (ADACCESS) https:\/\/clinicaltrials.gov\/show\/nct02016105"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: a randomised, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogova","year":"2020","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0140|cit140","unstructured":"MSB11022 in moderate to severe chronic plaque psoriasis (AURIEL-PsO) https:\/\/clinicaltrials.gov\/show\/nct02660580"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12325-021-01899-0","article-title":"Efficacy and safety of HLX03, an adalimumab biosimilar, in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, phase iii study","volume":"39","author":"Cai","year":"2022","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"71","DOI":"10.14412\/1996-7012-2018-4-71-84","article-title":"Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2\/CALYPSO phase III international, multicenter, randomized double-blind clinical trial","volume":"12","author":"Korotaeva","year":"2018","journal-title":"Modern Rheumatology Journal"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0143|cit143","unstructured":"Comparative clinical trial of efficacy and safety of BCD-057 and Humira\u00ae in patients with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct02762955"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0144|cit144","unstructured":"Comparative double-blind study of the efficacy and safety of BCD-057 and Humira\u00ae in patients with moderate to severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/03\/012598"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40259-021-00502-w","article-title":"Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase III study","volume":"35","author":"Feldman","year":"2021","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0146|cit146","unstructured":"A multicenter, double-blind, randomized, parallel-group, active control study to compare the efficacy, safety, and immunogenicity of AVT02 versus Humira\u00ae in patients with moderate-to-severe chronic plaque psoriasis (ALVOPAD PS) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-003367-35-PL"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0147|cit147","unstructured":"Phase 3 study of M923 and Humira\u00ae in subjects with chronic plaque-type psoriasis https:\/\/clinicaltrials.gov\/show\/nct02581345"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0149|cit149","unstructured":"Study to compare efficacy and safety of ABP 501 and adalimumab (HUMIRA\u00ae) in adults with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct01970488"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub7-BIB0150|cit150","first-page":"2879","article-title":"Switching from adalimumab to CHS-1420: a randomized, double-blind global clinical trial in patients with psoriasis and psoriatic arthritis","volume":"69","author":"Hodge","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD011535.pub7-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1002\/art.42355","article-title":"Efficacy and safety similarity of biosimilar adalimumab-aqvh to adalimumab in patients with moderate-to-severe chronic plaque psoriasis: a phase III study","volume":"74","author":"Finck","year":"2022","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0152|cit152","unstructured":"Comparison of CHS-1420 versus Humira in subjects with chronic plaque psoriasis (PsOsim) https:\/\/clinicaltrials.gov\/show\/nct02489227"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0153|cit153","unstructured":"A study to compare the efficacy and safety of CHS-1420 against Humira\u00ae https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-000632-15-EE"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14712598.2021.1851362","article-title":"Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized phase III VOLTAIRE-PSO study","volume":"21","author":"Menter","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0155|cit155","unstructured":"Efficacy, safety and immunogenicity of BI 695501 versus Humira\u00ae in patients with moderate to severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct02850965"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"AB5","DOI":"10.1016\/j.jaad.2020.06.108","article-title":"13097 Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks","volume":"83","author":"Menter","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"109248","DOI":"10.1016\/j.intimp.2022.109248","article-title":"A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis","volume":"112","author":"Yu","year":"2022","journal-title":"International Immunopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","article-title":"The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"176","author":"Griffiths","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.jid.2017.07.098","article-title":"Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis","volume":"137","author":"Griffiths","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0160|cit160","unstructured":"Study to demonstrate equivalent efficacy and to compare safety of biosimilar etanercept (GP2015) and Enbrel (EGALITY) https:\/\/clinicaltrials.gov\/show\/nct01891864"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jdv.14605","article-title":"Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study","volume":"32","author":"Gerdes","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0162|cit162","unstructured":"Comparison of CHS-0214 to Enbrel (etanercept) in patients with chronic plaque psoriasis (PsO) https:\/\/clinicaltrials.gov\/show\/nct02134210"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"AB128","DOI":"10.1016\/j.jaad.2017.04.500","article-title":"Evaluation of CHS-0214 as a proposed biosimilar to etanercept for the treatment of chronic plaque psoriasis: one-year results from a randomized, double-blind global trial","volume":"76","author":"Leonardi","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub7-BIB0164|cit164","first-page":"2142","article-title":"Randomized, double-blind study comparing CHS-0214 with etanercept (ENBREL) in patients with psoriasis and psoriatic arthritis","volume":"68","author":"Kivitz","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","article-title":"Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis","volume":"23","author":"Feldman","year":"2023","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0166|cit166","unstructured":"Efficacy, safety, and immunogenicity of AVT04 with moderate-to-severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/show\/NCT04930042"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0167|cit167","unstructured":"A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar ustekinumab (AVT04) and Stelara\u00ae in patients with moderate to severe chronic plaque-type psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-004493-22-PL"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"AB124","DOI":"10.1016\/j.jaad.2023.07.498","article-title":"42913 Assessment of therapeutic equivalence between candidate biosimilar AVT04 and reference ustekinumab","volume":"89","author":"Stroissnig","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","article-title":"A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate to severe plaque psoriasis","volume":"91","author":"Feldman","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0170|cit170","unstructured":"SB17 versus Stelara\u00ae in subjects with moderate to severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-006115-19-CZ"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0171|cit171","unstructured":"A study to compare SB17 (proposed ustekinumab biosimilar) to Stelara\u00ae in subject with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/NCT04967508"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0172|cit172","unstructured":"A study to investigate ABP 654 for the treatment of participants with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/NCT04607980"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0173|cit173","unstructured":"A study to investigate ABP 654 for the treatment of subjects with moderate to severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-003184-25-EE"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0174|cit174","unstructured":"Efficacy, safety, and immunogenicity of subcutaneous DMB-3115 versus Stelara\u00ae in patients with moderate to severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/show\/NCT04785326"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0175|cit175","unstructured":"Clinical study comparing DMB-3115 and Stelara\u00ae in patients with moderate to severe chronic plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-005108-21-HU"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","article-title":"Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study","volume":"38","author":"Papp","year":"2024","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0177|cit177","unstructured":"Study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-001045-39-EE"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0178|cit178","unstructured":"A phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with plaque psoriasis https:\/\/clinicaltrials.gov\/show\/NCT04673786"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","article-title":"Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study","volume":"38","author":"Papp","year":"2024","journal-title":"BioDrugs"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0180|cit180","first-page":"83","article-title":"Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial","volume":"6","author":"Bissonnette","year":"2013","journal-title":"Circulation: Cardiovascular Imaging"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00403-019-02024-6","article-title":"Etanercept biosimilar (recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial","volume":"312","author":"Liu","year":"2020","journal-title":"Archives of Dermatological Research"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0183|cit183","unstructured":"Optimizing psoriasis treatment of etanercept combined methotrexate https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02313922"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/1346-8138.16566","article-title":"Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris","volume":"49","author":"Morita","year":"2022","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0186|cit186","unstructured":"Comparison of phototherapy alone or together with apremilast in psoriasis vulgaris patients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCTs041180012"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/1346-8138.16566","article-title":"Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris","volume":"49","author":"Morita","year":"2022","journal-title":"Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jid.2022.01.033","article-title":"Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized controlled trial","volume":"142","author":"Kraaij","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0189|cit189","first-page":"25","article-title":"Optimizing adalimumab treatment in psoriasis with concomitant methotrexate: a randomized controlled trial","volume":"33","author":"Kraaij","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0190|cit190","unstructured":"Optimising adalimumab treatment in psoriasis with concomitant methotrexate \u2013 OPTIMAP https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-004918-18-NL"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0191|cit191","first-page":"52. Erratum in:","article-title":"Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial","volume":"18","author":"Busard","year":"2017","journal-title":"Trials [Electronic Resource]"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archderm.1990.01670280066012","article-title":"Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis","volume":"126","author":"Ruzicka","year":"1990","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0193|cit193","first-page":"218","article-title":"Randomized double-blind multicenter study comparing acitretin-PUVA, etritinate-PUVA and placebo-PUVA in the treatment of severe psoriasis","volume":"177","author":"Saurat","year":"1988","journal-title":"Dermatologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1468-3083.1993.tb00058.x","article-title":"Acitretin in combination with PUVA: a randomized double-blind placebo-controlled study in severe psoriasis","volume":"2","author":"Sommerburg","year":"1993","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"Laburte","year":"1994","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2340\/0001555577137141","article-title":"Low-dose (1.25 mg\/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile","volume":"77","author":"Meffert","year":"1997","journal-title":"Acta Dermato-Venereologica"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD011535.pub7-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(08)80766-9","article-title":"Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study","volume":"22","author":"Nugteren-Huying","year":"1990","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"49","key":"10.1002\/14651858.CD011535.pub7-BIB0199|cit199","first-page":"2387","article-title":"Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study","volume":"134","author":"Nugteren-Huying","year":"1990","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0200|cit200","unstructured":"A double-blind study in subjects with moderate to severe plaque psoriasis to evaluate efficacy, safety, tolerability of four different dose levels of ABY-035 compared to placebo https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-001615-36-DE"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0202|cit202","doi-asserted-by":"crossref","unstructured":"Krueger JG Garcet S Cheng J Kumar S Tang J Blau J Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis Journal of Investigative Dermatology 2024 144 8 Suppl S46 10.1016\/j.jid.2024.06.281","DOI":"10.1016\/j.jid.2024.06.281"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13555-023-01092-x","article-title":"Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)","volume":"14","author":"Reich","year":"2024","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0204|cit204","unstructured":"Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab (COBRA) https:\/\/clinicaltrials.gov\/show\/NCT04533737"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0205|cit205","unstructured":"A study to evaluate the efficacy, safety, and tolerability of an oral tablet formulation of JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-005987-23-FR"},{"issue":"11 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.1016\/j.jid.2023.09.085","article-title":"77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study","volume":"143","author":"Pinter","year":"2023","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0207|cit207","unstructured":"A phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis - FRONTIER 1: efficacy and safety of JNJ-77242113 in moderate to severe plaque psoriasis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-003700-41 2021"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0208|cit208","unstructured":"A long-term extension study of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-003700-41\/ES"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.1016\/j.jid.2023.09.086","article-title":"78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: efficacy of overall and scalp psoriasis responses from FRONTIER 1","volume":"143","author":"Bissonnette","year":"2023","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2024.03.025","article-title":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study","volume":"91","author":"Gebauer","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0211|cit211","unstructured":"Efficacy and safety of tildrakizumab in the treatment of scalp psoriasis https:\/\/clinicaltrials.gov\/show\/nct03897088"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","article-title":"Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","volume":"90","author":"Warren","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0213|cit213","unstructured":"Study to assess the efficacy and safety of orismilast in psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-003209-22-DE"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","article-title":"Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study","volume":"189","author":"Stein Gold","year":"2023","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0215|cit215","unstructured":"Study of subcutaneous risankizumab injection compared to oral apremilast tablets to assess adverse events and change in disease activity in adult participants with moderate plaque psoriasis who are candidates for systemic therapy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-005512-21-DE"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0216|cit216","unstructured":"Study of subcutaneous risankizumab injection compared to oral apremilast tablets to assess change in disease activity and adverse events in adult participants with moderate plaque psoriasis who are candidates for systemic therapy https:\/\/clinicaltrials.gov\/show\/NCT04908475"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","article-title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","volume":"189","author":"Stein Gold","year":"2023","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ced\/llae006","article-title":"Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab","volume":"49","author":"Tomalin","year":"2024","journal-title":"Clinical and Experimental Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ced\/llae006","article-title":"Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab","volume":"49","author":"Tomalin","year":"2024","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0221|cit221","unstructured":"A study of secukinumab treatment in patients with plaque psoriasis and coexisting non-alcoholic fatty liver disease (NAFLD) (pINPOINt) https:\/\/clinicaltrials.gov\/show\/NCT04237116"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0222|cit222","unstructured":"Study in patients with plaque psoriasis with coexisting non-alcoholic fatty liver disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-003168-37-DE"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0223|cit223","unstructured":"Study of subcutaneous (injected under the skin) risankizumab to assess change in disease symptoms in adult participants with moderate to severe plaque psoriasis with palmoplantar involvement https:\/\/clinicaltrials.gov\/show\/NCT04713592"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0224|cit224","unstructured":"A study to evaluate the efficacy and safety of bimekizumab in adult Korean study participants with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/NCT05020249"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.lanepe.2023.100639","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis \u2013 a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenlove","year":"2023","journal-title":"Lancet Regional Health \u2013 Europe"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaad.2024.02.036","article-title":"Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis \u2013 results from a randomized controlled trial (PSORRO)","volume":"91","author":"Gyldenlove","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/jdv.18812","article-title":"Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets","volume":"37","author":"Warren","year":"2023","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0228|cit228","unstructured":"A research study to evaluate the efficacy of LEO 32731 oral tablet formulation in patients with moderate to severe psoriasis vulgaris https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-005279-25-DE"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0229|cit229","first-page":"53","article-title":"Tepilamide fumarate (PPC-06) extended release tablets in patients with moderate-to-severe plaque psoriasis: safety and efficacy results from the randomized, double-blind, placebo-controlled AFFIRM study","volume":"15","author":"Mrowietz","year":"2022","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0230|cit230","unstructured":"A study to assess the efficacy and safety of PPC-06 (tepilamide fumarate) https:\/\/clinicaltrials.gov\/show\/nct03421197"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm\u00ae \u2013 and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.15922","article-title":"Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study","volume":"34","author":"de Kerkhof","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.15922","article-title":"Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study","volume":"34","author":"de Kerkhof","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"10068","key":"10.1002\/14651858.CD011535.pub7-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjd.18001","article-title":"Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways","volume":"181","author":"Reich","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","article-title":"Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis","volume":"75","author":"Bissonnette","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/1346-8138.13829","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial","volume":"44","author":"Ohtsuki","year":"2017","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0241|cit241","unstructured":"Efficacy and safety study of two doses of apremilast (CC-10004) in Japanese subjects with moderate-to-severe plaque-type psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01988103"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0242|cit242","first-page":"10","article-title":"Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: results from a phase 2b randomized trial","volume":"10","author":"Imafuku","year":"2020","journal-title":"Journal of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-11-82","article-title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study","volume":"10","author":"Strand","year":"2013","journal-title":"Health and Quality of Life Outcomes"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1111\/j.1468-3083.2012.04716.x","article-title":"Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study","volume":"27","author":"Papp","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Voorhees","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0246|cit246","unstructured":"Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-002481-31-LV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0247|cit247","unstructured":"Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2080223467"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0248|cit248","first-page":"55","article-title":"A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis","volume":"27","author":"Catlett","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0249|cit249","first-page":"29","article-title":"Evaluating influence of baseline characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2 trial","volume":"27","author":"Gordon","year":"2018","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0250|cit250","unstructured":"Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis https:\/\/clinicaltrials.gov\/show\/nct02931838"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0251|cit251","article-title":"A selective inhibitor of tyrosine kinase 2, bms-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis","volume":"12","author":"Catlett","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association (Conference: 24th World Congress of Dermatology, Italy)"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13555-021-00649-y","article-title":"Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial","volume":"12","author":"Thaci","year":"2022","journal-title":"Dermatology and Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0253|cit253","first-page":"32","article-title":"Influence of baseline demographics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Gooderham","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"S3","key":"10.1002\/14651858.CD011535.pub7-BIB0254|cit254","first-page":"71","article-title":"Selective oral tyrosine kinase 2 (TYK2) inhibitor (BMS-986165) impact on quality of life (QOL) in patients with moderate to severe plaque psoriasis (PSO) in a phase 2 trial as assessed by the dermatology life quality index (DLQI)","volume":"33","author":"Tha\u00e7i","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0255|cit255","first-page":"S26","article-title":"An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves health-related quality of life in psoriasis: results from a phase II trial","volume":"12","author":"Thaci","year":"2020","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/annrheumdis-2019-eular.1762","article-title":"Influence of baseline demographics and disease characteristics on efficacy of an oral, selective TYK2 inhibitor, BMS-986165, in patients with plaque psoriasis in a phase 2 trial","volume":"78","author":"Gordon","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0257|cit257","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo in participants with plaque psoriasis in mainland China, Taiwan, and South Korea (POETYK-PSO-3) https:\/\/clinicaltrials.gov\/show\/NCT04167462"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study","volume":"30","author":"Valenzuela","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0260|cit260","first-page":"AB150","article-title":"Etanercept therapy for moderate to severe plaque psoriasis with involvement of the scalp","volume":"64","author":"Bagel","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaad.2005.06.053","article-title":"Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial","volume":"53","author":"Feldman","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"Journal of Dermatological Treatment"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.jaad.2005.10.054","article-title":"Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial","volume":"54","author":"Krueger","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","article-title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial","volume":"153","author":"Krueger","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"9504","key":"10.1002\/14651858.CD011535.pub7-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1468-3083.2011.04394.x","article-title":"Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept","volume":"27","author":"Tyring","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2133.2007.08205.x","article-title":"Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks","volume":"157","author":"Krishnan","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0273|cit273","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"de Kerkhof","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000237871","article-title":"Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis","volume":"219","author":"Reich","year":"2009","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","article-title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II\/III randomized controlled study","volume":"37","author":"Asahina","year":"2010","journal-title":"Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011535.pub7-BIB0277|cit277","first-page":"65","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase-3, randomized, placebo-controlled trial","volume":"30","author":"Elewski","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1136\/annrheumdis-2017-eular.2148","article-title":"Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","volume":"76","author":"Elewski","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0280|cit280","first-page":"26","article-title":"Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","volume":"98","author":"Elewski","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09546630601121060","article-title":"Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial","volume":"18","author":"Shikiar","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"27","author":"Shikiar","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40257-016-0229-x","article-title":"Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab","volume":"17","author":"Armstrong","year":"2016","journal-title":"American Journal of Clinical Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1468-3083.2012.04515.x","article-title":"Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study","volume":"27","author":"Papp","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11530640-000000000-00000","article-title":"Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial","volume":"12","author":"Kimball","year":"2011","journal-title":"American Journal of Clinical Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circulation. Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0292|cit292","unstructured":"Vascular Inflammation in psoriasis trial (the VIP trial) (VIP) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01553058"},{"issue":"9494","key":"10.1002\/14651858.CD011535.pub7-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial","volume":"154","author":"Reich","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000317775","article-title":"Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS trial","volume":"221","author":"Reich","year":"2010","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","article-title":"Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis","volume":"159","author":"Feldman","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0298|cit298","first-page":"381","article-title":"Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis","volume":"17","author":"Reich","year":"2007","journal-title":"European Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"Journal of Dermatological Science"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0302|cit302","unstructured":"Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasis https:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-060318"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0303|cit303","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial","volume":"125","author":"Yang","year":"2012","journal-title":"Chinese Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0305|cit305","first-page":"13","article-title":"Long-term health-related quality of life in patients with plaque psoriasis treated with certolizumab pegol: three-year results from two randomised phase 3 studies (CIMPASI-1 and CIMPASI-2)","volume":"13","author":"Gisondi","year":"2022","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0306|cit306","unstructured":"An efficacy and safety study of two dose levels of certolizumab pegol (CZP) in subjects with plaque psoriasis (PSO) https:\/\/clinicaltrials.gov\/show\/nct02326298"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0308|cit308","unstructured":"A study to evaluate the efficacy and safety of two dose levels of certolizumab pegol (CZP) in subjects with plaque psoriasis (PSO) (CIMPASI-2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02326272"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13555-021-00494-z","article-title":"Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase 2\/3 Japanese study","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0310|cit310","unstructured":"A study to test the efficacy and safety of certolizumab pegol in Japanese subjects with moderate to severe chronic psoriasis https:\/\/clinicaltrials.gov\/show\/nct03051217"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0311|cit311","first-page":"19","article-title":"Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase 2\/3 Japanese study","volume":"19","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","article-title":"Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13555-021-00645-2","article-title":"Certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: effect of demographics and baseline disease characteristics on efficacy","volume":"12","author":"Imafuku","year":"2022","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1346-8138.2012.01521.x","article-title":"Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2\/3 trial","volume":"39","author":"Nakagawa","year":"2012","journal-title":"Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0317|cit317","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu","year":"2013","journal-title":"Journal of Drugs in Dermatology"},{"issue":"s1","key":"10.1002\/14651858.CD011535.pub7-BIB0318|cit318","first-page":"238","article-title":"A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results","volume":"39","author":"Zheng","year":"2012","journal-title":"Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0319|cit319","first-page":"521","article-title":"Ustekinumab improves health-related quality of life in Chinese patients with moderate-to-severe plaque psoriasis: results from the LOTUS trial and curative effect observation","volume":"43","author":"Zheng","year":"2014","journal-title":"Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"Journal of Dermatological Science"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0321|cit321","first-page":"943","article-title":"Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial","volume":"11","author":"Tsai","year":"2012","journal-title":"Journal of Drugs in Dermatology"},{"issue":"9625","key":"10.1002\/14651858.CD011535.pub7-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1468-3083.2011.04082.x","article-title":"Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials","volume":"25","author":"Guenther","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10928-011-9191-7","article-title":"Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis","volume":"38","author":"Hu","year":"2011","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0329|cit329","first-page":"300","article-title":"An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up","volume":"11","author":"Reich","year":"2012","journal-title":"Journal of Drugs in Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0091270009343695","article-title":"Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis","volume":"50","author":"Zhou","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"9625","key":"10.1002\/14651858.CD011535.pub7-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09546634.2010.499931","article-title":"Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2","volume":"22","author":"Reich","year":"2011","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0338|cit338","unstructured":"Study of efficacy and safety of secukinumab 2 mL pre-filled syringe (300 mg) in subjects with moderate to severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-005170-38-BE"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0339|cit339","unstructured":"Study of secukinumab with 2 mL pre-filled syringes (ALLURE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02748863"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/09546634.2021.1902925","article-title":"Efficacy, tolerability, patient usability, and satisfaction with a 2\u2009mL pre-filled syringe containing secukinumab 300\u2009mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study","volume":"33","author":"Sigurgeirsson","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0341|cit341","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1080\/09546634.2021.1902925","article-title":"Efficacy, tolerability, patient usability, and satisfaction with a 2\u2009mL pre-filled syringe containing secukinumab 300\u2009mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study","volume":"33","author":"Sigurgeirsson","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"issue":"22","key":"10.1002\/14651858.CD011535.pub7-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0343|cit343","unstructured":"Study of efficacy and safety of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis https:\/\/clinicaltrials.gov\/show\/nct03066609"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0344|cit344","first-page":"AB445","article-title":"Secukinumab 300 mg showed faster and higher efficacy in Chinese moderate to severe plaque psoriasis patients","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0345|cit345","unstructured":"A randomised, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis comorbidity www.thaiclinicaltrials.org\/show\/TCTR20161028001"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0347|cit347","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/1346-8138.12668","article-title":"Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study","volume":"41","author":"Ohtsuki","year":"2014","journal-title":"Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jdv.14073","article-title":"Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial","volume":"31","author":"Lacour","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0352|cit352","doi-asserted-by":"publisher","first-page":"e15285","DOI":"10.1111\/dth.15285","article-title":"Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2\u2009ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial","volume":"35","author":"Sigurgeirsson","year":"2022","journal-title":"Dermatology Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0353|cit353","unstructured":"Study of efficacy and safety of secukinumab 2 mL auto-injector (300 mg) in subjects with moderate to severe plaque psoriasis (MATURE) https:\/\/clinicaltrials.gov\/show\/nct03589885"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0354|cit354","unstructured":"Study of efficacy and safety of secukinumab 2 mL auto-injector (300 mg) injections in subjects with moderate to severe plaque psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-000518-39-DE"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"AB154","DOI":"10.1016\/j.jaad.2021.06.630","article-title":"27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE","volume":"85","author":"Sigurgeirsson","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"e15285","DOI":"10.1111\/dth.15285","article-title":"Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2\u2009ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial","volume":"35","author":"Sigurgeirsson","year":"2022","journal-title":"Dermatologic Therapy"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0357|cit357","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet. Rheumatology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0358|cit358","first-page":"S26","article-title":"Efficacy and safety of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe psoriasis: 52-week results from OASIS-2, a multicenter, randomized, double-blind study","volume":"14","author":"Papp","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0359|cit359","unstructured":"A study to assess if mirikizumab is effective and safe compared to secukinumab and placebo in moderate to severe plaque psoriasis (OASIS-2) https:\/\/clinicaltrials.gov\/show\/nct03535194"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"AB38","DOI":"10.1016\/j.jaad.2020.06.239","article-title":"15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis","volume":"83","author":"Krueger","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"AB37","DOI":"10.1016\/j.jaad.2020.06.234","article-title":"15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis","volume":"83","author":"Krueger","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0362|cit362","unstructured":"Study to explore the effect of secukinumab, compared to placebo, on fat tissue and skin in plaque psoriasis patients (ObePso-S) https:\/\/clinicaltrials.gov\/show\/nct03055494"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0363|cit363","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","article-title":"Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study","volume":"109","author":"Blauvelt","year":"2023","journal-title":"Journal of Dermatological Science"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jdv.12343","article-title":"Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and\/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study","volume":"28","author":"Sigurgeirsson","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.13478","article-title":"Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response \u2013 results of a phase II regimen-finding trial","volume":"30","author":"Augustin","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/annrheumdis-2016-eular.5018","article-title":"Secukinumab shows significant efficacy in nail psoriasis: week 32 results from the TRANSFIGURE study","volume":"75","author":"Reich","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo controlled trial of secukinumab on aortic vascular inflammation in moderate to severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0371|cit371","unstructured":"Study to evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in subjects with moderate to severe plaque psoriasis (VIP-S) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02690701"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jdv.13032","article-title":"A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab","volume":"30","author":"Edson-Heredia","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2014.07.048","article-title":"A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis","volume":"71","author":"Gordon","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jcph.312","article-title":"Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis","volume":"54","author":"Tham","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bjd.12610","article-title":"Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis","volume":"169","author":"Zhu","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/bjd.13065","article-title":"Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial","volume":"171","author":"Zhu","year":"2014","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0378|cit378","unstructured":"A study of ixekizumab (LY2439821) in Chinese participants with moderate-to-severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct03364309"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"AB55","DOI":"10.1016\/j.jaad.2021.06.246","article-title":"25258 Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study","volume":"85","author":"Rui","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0380|cit380","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/JD9.0000000000000244","article-title":"Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study","volume":"5","author":"Li","year":"2022","journal-title":"Chinese Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","article-title":"Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials","volume":"152","author":"Armstrong","year":"2016","journal-title":"JAMA Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"AB164","DOI":"10.1016\/j.jaad.2020.06.743","article-title":"15921 Absolute PASI response up to 52 weeks with brodalumab in patients with moderate to severe plaque psoriasis","volume":"83","author":"Armstrong","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"Journal of Dermatological Science"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jdv.13785","article-title":"Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis","volume":"30","author":"Umezawa","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjd.12636","article-title":"Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory","volume":"170","author":"Gordon","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaad.2014.10.026","article-title":"Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis","volume":"72","author":"Papp","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/1346-8138.15733","article-title":"Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: a randomized, phase III, double-blind, placebo-controlled study","volume":"48","author":"Seo","year":"2021","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0391|cit391","unstructured":"A study of KHK4827 (brodalumab) in subjects with moderate to severe psoriasis in Korea https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02982005"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0392|cit392","unstructured":"Study to evaluate safety and efficacy of different doses of bimekizumab in patients with chronic plaque psoriasis (BE ABLE 1) https:\/\/clinicaltrials.gov\/show\/nct02905006"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0393|cit393","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10273","key":"10.1002\/14651858.CD011535.pub7-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0395|cit395","unstructured":"A study with an initial treatment period followed by a randomized-withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE READY) https:\/\/clinicaltrials.gov\/show\/nct03410992"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"AB139","DOI":"10.1016\/j.jaad.2021.06.573","article-title":"27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0397|cit397","unstructured":"International clinical trial to evaluate efficacy and safety of multiple subcutaneous injections of BCD-085 in various doses in patients with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct02762994"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0398|cit398","doi-asserted-by":"publisher","first-page":"39","DOI":"10.30906\/0869-2092-2019-82-6-39-44","article-title":"Results of treatment of patients suffering of plaque psoriasis and psoriatic onychodystrophy by BCD-085: analysis of phase II clinical investigation","volume":"82","author":"Artem'eva","year":"2019","journal-title":"Eksperimental'naya I Klinicheskaya Farmakologiya"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0399|cit399","first-page":"31","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"31","author":"Puig","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0400|cit400","article-title":"Netakimab: 12-week results from PLANETA study, a phase III trial of a novel IL-17 inhibitor in moderate-to-severe plaque psoriasis","volume":"12","author":"Andrey","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0402|cit402","unstructured":"An efficacy and safety of CNTO 1959 (guselkumab) in participants with moderate to severe plaque-type psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02325219"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0404|cit404","unstructured":"Efficacy and safety study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02905331"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0405|cit405","first-page":"29","article-title":"Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: results from the phase III ORION self-dose study through week 16","volume":"98","author":"Ferris","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0406|cit406","article-title":"Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: results from the phase III Orion self-dose study through week 16","volume":"12","author":"Ferris","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"10091","key":"10.1002\/14651858.CD011535.pub7-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0408|cit408","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"10091","key":"10.1002\/14651858.CD011535.pub7-BIB0409|cit409","first-page":"230","article-title":"Erratum: Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (Lancet 2017; 390(10091):276-288)","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0410|cit410","unstructured":"A study to evaluate the efficacy and safety of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis (MK-3222-010) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01722331"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0411|cit411","first-page":"110","article-title":"Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: results from long-term extensions of 2 phase 3 studies","volume":"59","author":"Reich","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1080\/09546634.2021.1914812","article-title":"Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis","volume":"33","author":"Blauvelt","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0413|cit413","unstructured":"A study to assess safety and efficacy of risankizumab using a new formulation in participants with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct03875482"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0414|cit414","first-page":"e248","article-title":"Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial","volume":"177","author":"Blauvelt","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0415|cit415","first-page":"30","article-title":"Risankizumab efficacy\/safety in moderate-to-severe plaque psoriasis: 16-week results from IMMhance","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0416|cit416","unstructured":"BI 655066\/ABBV-066 (risankizumab) in moderate to severe plaque psoriasis with randomized withdrawal and re-treatment https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02672852"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0417|cit417","first-page":"18","article-title":"Efficacy and safety of risankizumab, an IL-23 inhibitor in patients with moderate-to-severe chronic plaque psoriasis: 16-week phase 3 IMMhance trial results","volume":"16","author":"Blauvelt","year":"2018","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s13555-022-00776-0","article-title":"Risankizumab for the treatment of moderate to severe plaque psoriasis in the Russian Federation","volume":"12","author":"Odnopozova","year":"2022","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0419|cit419","unstructured":"Risankizumab therapy versus placebo for subjects with psoriasis in the Russian Federation (IMMPRESS) https:\/\/clinicaltrials.gov\/show\/nct03518047"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0421|cit421","unstructured":"BI 655066 (risankizumab) compared to placebo in Japanese patients with moderate to severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct03000075"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0422|cit422","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstr\u00f6m","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archderm.140.6.685","article-title":"Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine","volume":"140","author":"Opmeer","year":"2004","journal-title":"Archives of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00403-002-0353-8","article-title":"Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ","volume":"294","author":"Piskin","year":"2003","journal-title":"Archives of Dermatological Research"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1346-8138.2003.tb00416.x","article-title":"Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from North India","volume":"30","author":"Sandhu","year":"2003","journal-title":"Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0428|cit428","unstructured":"A comparison of the efficacy of oral fumarate and methotrexate therapy in the treatment of severe psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN76608307"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12895-016-0048-z","article-title":"A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"Sticherling","year":"2017","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0432|cit432","unstructured":"Study of secukinumab compared to Fumaderm\u00ae in adults with moderate to severe psoriasis (PRIME) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02474082"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0433|cit433","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjd.18696","article-title":"Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are na\u00efve to systemic treatment: results from a randomised, active comparator-controlled phase 3b trial (POLARIS)","volume":"183","author":"Tha\u00e7i","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0434|cit434","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljad523","article-title":"Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-na\u00efve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)","volume":"191","author":"Tha\u00e7i","year":"2024","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0435|cit435","unstructured":"A study to compare the efficacy of guselkumab to fumaric acid esters for the treatment of participants with moderate to severe plaque psoriasis (POLARIS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02951533"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0436|cit436","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljad523","article-title":"Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-na\u00efve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)","volume":"191","author":"Tha\u00e7i","year":"2023","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjd.20481","article-title":"Direct comparison of risankizumab and fumaric acid esters in systemic-therapy-naive patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"186","author":"Tha\u00e7i","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0438|cit438","unstructured":"A study to assess the efficacy of risankizumab compared to FUMADERM\u00ae in subjects with moderate to severe plaque psoriasis who are naive to and candidates for systemic therapy https:\/\/clinicaltrials.gov\/show\/nct03255382"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.17109","article-title":"Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naive patients with moderate to severe plaque psoriasis: a phase 3 clinical trial","volume":"35","author":"Tha\u00e7i","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjd.20481","article-title":"Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naive patients with moderate-to-severe plaque psoriasis: a randomized controlled trial","volume":"186","author":"Tha\u00e7i","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jdv.16932","article-title":"A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"35","author":"Pinter","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0442|cit442","unstructured":"A trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct03331835"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0443|cit443","first-page":"16","article-title":"A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"16","author":"Pinter","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1468-3083.2010.03838.x","article-title":"Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial","volume":"25","author":"Prinz","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/09546634.2017.1329509","article-title":"Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe","volume":"29","author":"Damjanov","year":"2018","journal-title":"Journal of Dermatological Treatment"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjd.13139","article-title":"Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept","volume":"172","author":"Griffiths","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0450|cit450","first-page":"11","article-title":"Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial","volume":"33","author":"Kirkham","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/09546634.2012.658015","article-title":"The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)","volume":"24","author":"Strohal","year":"2013","journal-title":"Journal of Dermatological Treatment"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/jdv.12207","article-title":"Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial","volume":"28","author":"Tha\u00e7i","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/09546634.2013.860209","article-title":"Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis","volume":"26","author":"Puig","year":"2015","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bjd.14867","article-title":"A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study","volume":"176","author":"De Vries","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0455|cit455","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/eci.10.92","article-title":"The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients","volume":"7","author":"Young","year":"2011","journal-title":"Expert Review of Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial","volume":"186","author":"Augustin","year":"2022","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0458|cit458","unstructured":"Efficacy and safety of 2 secukinumab regimens in 90 kg or higher subjects with moderate to severe chronic plaque-type psoriasis https:\/\/clinicaltrials.gov\/show\/nct03504852"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0460|cit460","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjd.18623","article-title":"Secukinumab for patients failing previous tumour necrosis factor-alpha inhibitor therapy: results of a randomized open-label study (SIGNATURE)","volume":"183","author":"Warren","year":"2019","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0461|cit461","unstructured":"Secukinumab in TNF-IR psoriasis patients (SIGNATURE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01961609"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatology and Therapy"},{"issue":"4 Supp 1","key":"10.1002\/14651858.CD011535.pub7-BIB0463|cit463","first-page":"AB274","article-title":"Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0464|cit464","doi-asserted-by":"crossref","unstructured":"Bagel J Blauvelt A Nia J Hashim P Patekar M de Vera A Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY) Journal of the European Academy of Dermatology and Venereology: JEADV 2021 35 1 135 42 10.1111\/jdv.16558","DOI":"10.1111\/jdv.16558"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0465|cit465","first-page":"S27","article-title":"Secukinumab is superior to ustekinumab in clearing skin of patients with moderate-to-severe plaque psoriasis: CLARITY, a randomized, controlled, Phase IIIb trial","volume":"11","author":"Bagel","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0466|cit466","unstructured":"Study of secukinumab compared to ustekinumab in subjects with plaque psoriasis (CLARITY) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02826603"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub7-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/jdv.14391","article-title":"Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study","volume":"31","author":"Blauvelt","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0470|cit470","first-page":"S15","article-title":"Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis","volume":"10","author":"Blauvelt","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0471|cit471","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0472|cit472","first-page":"86","article-title":"Secukinumab 300 mgs is more efficacious than ustekinumab 90 mgs: analysis of patients with body weights over 100kg from the CLEAR study","volume":"58","author":"Spelman","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0473|cit473","first-page":"S17","article-title":"Secukinumab delivers greater improvement in health-related quality of life compared to ustekinumab in subjects with moderate-to-severe plaque psoriasis: 16-week data from the CLEAR study","volume":"9","author":"Tha\u00e7i","year":"2016","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0474|cit474","first-page":"S18","article-title":"Secukinumab 300mg is more efficacious than ustekinumab 90mg: analysis of the CLEAR study","volume":"10","author":"Herranz","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"10201","key":"10.1002\/14651858.CD011535.pub7-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0476|cit476","unstructured":"A study to evaluate the comparative efficacy of CNTO 1959 (guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE) https:\/\/clinicaltrials.gov\/show\/nct03090100"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"AB34","DOI":"10.1016\/j.jaad.2020.06.225","article-title":"15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: findings from the ECLIPSE study","volume":"83","author":"Langley","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/09546634.2021.1959504","article-title":"Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study","volume":"33","author":"Blauvelt","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0479|cit479","first-page":"58","article-title":"Consistent responses to guselkumab by disease region at week 48 in the treatment of moderate-to-severe psoriasis: ECLIPSE trial results","volume":"62","author":"Langley","year":"2021","journal-title":"Australasian Journal of Dermatology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0480|cit480","first-page":"S24","article-title":"Guselkumab demonstrates greater efficacy compared to secukinumab across body weight quartiles and body mass index categories: week 48 results from the ECLIPSE trial","volume":"12","author":"Armstrong","year":"2020","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0482|cit482","unstructured":"A study comparing different dosing regimens of ixekizumab (LY2439821) in participants with moderate to severe plaque psoriasis (IXORA-P) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02513550"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0483|cit483","first-page":"44","article-title":"Absolute and relative PASI improvements with ixekizumab treatment: results at week 12 from IXORA-P","volume":"98","author":"Papp","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0485|cit485","unstructured":"A study of Ixekizumab (LY2439821) in participants with moderate-to-severe plaque psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02561806"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0486|cit486","first-page":"AB113","article-title":"Rapid clinical response predicts consistent long-term response in patients with moderate-to-severe psoriasis: Ixekizumab vs. ustekinumab","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2019.1587146","article-title":"Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial","volume":"31","author":"Blauvelt","year":"2020","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub7-BIB0488|cit488","first-page":"1827","article-title":"Comparison of ixekizumab and ustekinumab efficacy in the treatment of nail lesions of patients with moderate-to-severe plaque psoriasis: 24-week data from a phase 3 trial","volume":"69","author":"Ghislain","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study","volume":"80","author":"Paul","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0490|cit490","first-page":"55","article-title":"Ixekizumab provides greater cumulative benefits versus ustekinumab over 24 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blind phase 3b clinical trial","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub7-BIB0491|cit491","first-page":"A902","article-title":"Ixekizumab treatment leads to early resolution of bothersome symptoms versus ustekinumab","volume":"20","author":"Burge","year":"2017","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0492|cit492","first-page":"43","article-title":"Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: a randomised head-to-head trial","volume":"58","author":"Burkhardt","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0493|cit493","first-page":"41","article-title":"Comparison of ixekizumab with ustekinumab in patients with baseline PASI > 15 and\/or at-least 3-previous-non-biologic-therapies-treatment-failures: 24-week post-hoc-analysis from a randomized trial (IXORA-S;NCT02561806)","volume":"59","author":"Burkhardt","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jid.2018.03.484","article-title":"Consistency of response across subgroups of patients with moderate-to-severe plaque psoriasis following 52 weeks of treatment with ixekizumab compared to ustekinumab","volume":"138","author":"Paul","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0495|cit495","first-page":"e293","article-title":"52-week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Paul","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"19","key":"10.1002\/14651858.CD011535.pub7-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3700","article-title":"An analysis of patient-reported outcomes in ixora-s: comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis","volume":"100","author":"Puig","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0497|cit497","doi-asserted-by":"crossref","unstructured":"Blauvelt A Leonardi C Elewski B Crowley JJ Guenther LC Gooderham M A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial British Journal of Dermatology 2021 184 6 1047 58 10.1111\/bjd.19509","DOI":"10.1111\/bjd.19509"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0498|cit498","unstructured":"A study of ixekizumab (LY2439821) compared to guselkumab in participants with moderate-to-severe plaque psoriasis (IXORA-R) https:\/\/clinicaltrials.gov\/show\/nct03573323"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0499|cit499","first-page":"S20","article-title":"A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate to severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blind trial","volume":"12","author":"Blauvelt","year":"2020","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.jid.2021.02.679","article-title":"649 Validation of the Optimal Psoriasis Assessment Tool (OPAT) as a method of assessing psoriasis severity and impact from physician and patient perspectives","volume":"141","author":"Leonardi","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"AB19","DOI":"10.1016\/j.jaad.2020.06.163","article-title":"14152 Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate to severe plaque psoriasis","volume":"83","author":"Blauvelt","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0503|cit503","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14712598.2021.1843629","article-title":"A randomized controlled ixekizumab vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis","volume":"21","author":"AlMutairi","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5114\/ada.2019.91496","article-title":"Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature","volume":"38","author":"AlMutairi","year":"2021","journal-title":"Postepy Dermatologii I Alergologii"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub7-BIB0506|cit506","first-page":"2723","article-title":"Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study","volume":"72","author":"Kristensen","year":"2020","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0507|cit507","first-page":"ii10","article-title":"Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes","volume":"59","author":"Edwards","year":"2020","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0508|cit508","first-page":"5266","article-title":"A head-to-head comparison of ixekizumab and adalimumab in biologic-na\u00efve patients with active psoriatic arthritis: efficacy and safety outcomes from a randomized, open-label, blinded assessor study through 52 weeks","volume":"71","author":"Smolen","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 245","key":"10.1002\/14651858.CD011535.pub7-BIB0509|cit509","first-page":"7S","article-title":"Ixekizumab vs. adalimumab for the treatment of psoriatic arthritis: 52-week efficacy and safety outcomes","volume":"150","author":"Edwards","year":"2020","journal-title":"Swiss Medical Weekly"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0510|cit510","first-page":"70","article-title":"Efficacy of ixekizumab vs. adalimumab in patients with psoriatic arthritis with moderate-to-severe psoriasis: 52-week results from a multicentre, randomized, open-label study","volume":"183","author":"Kleyn","year":"2020","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0511|cit511","first-page":"28","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"28","author":"Mease","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0513|cit513","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/annrheumdis-2020-eular.3996","article-title":"Head-to-head study evaluating the combined ACR50\/PASI100 treatment response of ixekizumab versus adalimumab: individual patient data from a randomized, open label study in biologic-naive patients with psoriatic arthritis through week 52","volume":"79","author":"Kavanaugh","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"AB12","DOI":"10.1016\/j.jaad.2020.06.137","article-title":"13771 Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate to severe psoriasis: 24-week results from a multicenter, randomized, open-label, rater-blinded study (SPIRIT-H2H)","volume":"83","author":"Smith","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0515|cit515","unstructured":"Comparison of ixekizumab with adalimumab in patients with psoriatic arthritis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2017\/09\/009850"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0516|cit516","first-page":"S140","article-title":"Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PSA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomized open-label study","volume":"27","author":"Kristensen","year":"2021","journal-title":"Journal of Clinical Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/annrheumdis-2019-eular.8709","article-title":"Multicentre, randomised, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs: 24-week results","volume":"78","author":"Mease","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0518|cit518","first-page":"1437","article-title":"Patient-reported outcomes from a randomised, open-label, parallel-group study evaluating ixekizumab versus adalimumab in patients with PSA who are biologic DMARD na\u00efve: 24-week results","volume":"71","author":"den Bosch","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"10198","key":"10.1002\/14651858.CD011535.pub7-BIB0519|cit519","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0520|cit520","unstructured":"BI 655066 (risankizumab) versus adalimumab in a randomised, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and after inadequate adalimumab treatment response (IMMvent) - BI 655066 (risankizumab) versus adalimumab https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number%3A2015-003623-65\/EUCTR2015-003623-65"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0521|cit521","unstructured":"BI 655066\/ABBV-066 (risankizumab) compared to active comparator (adalimumab) in patients with moderate to severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct02694523"},{"issue":"16","key":"10.1002\/14651858.CD011535.pub7-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0523|cit523","unstructured":"BI 655066 dose ranging in psoriasis, active comparator ustekinumab https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02054481"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0524|cit524","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0525|cit525","unstructured":"Risankizumab versus secukinumab for subjects with moderate to severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct03478787"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"AB88","DOI":"10.1016\/j.jaad.2021.06.375","article-title":"26197 Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil","volume":"85","author":"Cestari","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0527|cit527","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0528|cit528","doi-asserted-by":"publisher","first-page":"AB184","DOI":"10.1016\/j.jaad.2023.07.739","article-title":"42664 Itching in patients with moderate to severe plaque psoriasis: the relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial","volume":"89","author":"Augustin","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0529|cit529","doi-asserted-by":"crossref","first-page":"AB25","DOI":"10.1016\/j.jaad.2022.06.133","article-title":"31069 Bimekizumab versus secukinumab in plaque psoriasis: reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial","volume":"87","author":"Augustin","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0530|cit530","unstructured":"A study to evaluate the efficacy and safety of bimekizumab compared to an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE RADIANT) https:\/\/clinicaltrials.gov\/show\/nct03536884"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0531|cit531","first-page":"S23","article-title":"Bimekizumab versus secukinumab in plaque psoriasis: higher efficacy translates into benefits in patient-perceived symptoms and health-related quality of life in the BE RADIANT multicenter, randomized, double blinded phase 3b trial","volume":"15","author":"Augustin","year":"2022","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0532|cit532","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0533|cit533","unstructured":"A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE SURE) https:\/\/clinicaltrials.gov\/show\/nct03412747"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0534|cit534","first-page":"S21","article-title":"Bimekizumab efficacy and safety versus adalimumab in patients with moderate-to-severe plaque psoriasis: results from a multicenter, randomized, double-blinded active comparator-controlled phase III trial (BE SURE)","volume":"14","author":"Warren","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0535|cit535","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0536|cit536","first-page":"554","article-title":"Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis","volume":"13","author":"Navarini","year":"2014","journal-title":"Journal of Drugs in Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0537|cit537","first-page":"864","article-title":"Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis","volume":"14","author":"Prussick","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0538|cit538","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","article-title":"Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial","volume":"63","author":"Reich","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0539|cit539","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10399.x","article-title":"Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study","volume":"165","author":"Saurat","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"9993","key":"10.1002\/14651858.CD011535.pub7-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"9993","key":"10.1002\/14651858.CD011535.pub7-BIB0542|cit542","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","volume":"31","author":"de Kerkhof","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept, and placebo, in patients with moderate to severe plaque psoriasis: 52-week results from a phase 3b, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0546|cit546","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0547|cit547","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0548|cit548","doi-asserted-by":"publisher","first-page":"AB235","DOI":"10.1016\/j.jaad.2023.07.941","article-title":"43927 the impact of treatment with guselkumab on skin-related quality of life in male and female patients with moderate to severe psoriasis: results from the VOYAGE 1 and 2 trials","volume":"89","author":"Armstrong","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0549|cit549","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in patient-reported outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"20","author":"Armstrong","year":"2018","journal-title":"American Journal of Clinical Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub7-BIB0550|cit550","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/annrheumdis-2018-eular.5825","article-title":"Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 VOYAGE 1 trial","volume":"77","author":"Griffiths","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40257-020-00555-7","article-title":"Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study","volume":"21","author":"Reich","year":"2020","journal-title":"American Journal of Clinical Dermatology"},{"issue":"14","key":"10.1002\/14651858.CD011535.pub7-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0554|cit554","first-page":"S26","article-title":"Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis: data from a pivotal phase III clinical trial","volume":"11","author":"Menter","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0555|cit555","first-page":"S23","article-title":"Maintenance of clinical efficacy in moderate-to-severe plaque psoriasis: a 52-week evaluation of brodalumab in three multicenter, double-blind studies of 4363 subjects","volume":"10","author":"Papp","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s13555-021-00545-5","article-title":"Dermatology Life Quality Index in patients with moderate-to-severe plaque psoriasis treated with brodalumab or ustekinumab","volume":"11","author":"Lambert","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"14","key":"10.1002\/14651858.CD011535.pub7-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0559|cit559","unstructured":"Efficacy and safety study of certolizumab pegol (CZP) versus active comparator and placebo in subjects with plaque psoriasis (PSO) (CIMPACT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02346240"},{"issue":"10091","key":"10.1002\/14651858.CD011535.pub7-BIB0560|cit560","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0561|cit561","unstructured":"A study to evaluate the efficacy and safety\/tolerability of subcutaneous tildrakizumab (SCH 900222\/MK-3222) in participants with moderate-to-severe chronic plaque psoriasis followed by a long-term extension study (MK-3222-011) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01729754"},{"issue":"10148","key":"10.1002\/14651858.CD011535.pub7-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub7-BIB0563|cit563","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"S3","key":"10.1002\/14651858.CD011535.pub7-BIB0564|cit564","first-page":"20","article-title":"High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Gooderham","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0565|cit565","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/exd.14067","article-title":"High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis","volume":"32","author":"Gooderham","year":"2023","journal-title":"Experimental Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0566|cit566","first-page":"28","article-title":"Efficacy and safety of risankizumab: results from two double-blind, placebo-and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0567|cit567","unstructured":"BI 655066 compared to placebo & active comparator (Ustekinumab) in patients with moderate to severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684357"},{"issue":"10148","key":"10.1002\/14651858.CD011535.pub7-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub7-BIB0569|cit569","first-page":"28","article-title":"Efficacy and safety of risankizumab: results from two double-blind, placebo-and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0570|cit570","unstructured":"BI 655066 (risankizumab) compared to placebo and active comparator (Ustekinumab) in patients with moderate to severe chronic plaque psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684370"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"Stebut","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0572|cit572","unstructured":"Evaluation of cardiovascular risk markers in psoriasis patients treated with secukinumab (CARIMA) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02559622"},{"issue":"10273","key":"10.1002\/14651858.CD011535.pub7-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0574|cit574","unstructured":"A study to evaluate the efficacy and safety of bimekizumab compared to placebo and an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE VIVID) https:\/\/clinicaltrials.gov\/show\/nct03370133"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0575|cit575","first-page":"S23","article-title":"Bimekizumab versus ustekinumab in plaque psoriasis: lasting efficacy translates to rapid and sustained improvements in quality of life in the BE VIVID multicenter, randomized, double-blinded phase III trial","volume":"14","author":"Gordon","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0576|cit576","first-page":"e38","article-title":"Bimekizumab versus ustekinumab in plaque psoriasis: lasting efficacy translates to rapid and sustained improvements in quality of life in the BE VIVID multicentre, randomized, double-blinded phase III trial","volume":"187","author":"Gordon","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0577|cit577","first-page":"S22","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase III trial","volume":"14","author":"Papp","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0578|cit578","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s13555-022-00883-y","article-title":"Bimekizumab efficacy and safety in Japanese patients with plaque psoriasis in BE VIVID: a phase 3, ustekinumab and placebo-controlled study","volume":"13","author":"Asahina","year":"2023","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0579|cit579","unstructured":"A phase 2b study of the efficacy, safety, and tolerability of M1095 in subjects with moderate to severe psoriasis https:\/\/clinicaltrials.gov\/show\/nct03384745"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0580|cit580","doi-asserted-by":"crossref","unstructured":"Armstrong AW Gooderham M Warren RB Papp KA Strober B Tha\u00e7i D Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial Journal of the American Academy of Dermatology 2023 88 1 29 39 10.1016\/j.jaad.2022.07.002 35820547","DOI":"10.1016\/j.jaad.2022.07.002"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0581|cit581","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0582|cit582","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1055\/a-2054-6560","article-title":"Plaque psoriasis: deucravacitinib versus placebo and apremilast, respectively","volume":"49","author":"Lorenz","year":"2023","journal-title":"Aktuelle Dermatologie"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0583|cit583","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis https:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-184213"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub7-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"AB156","DOI":"10.1016\/j.jaad.2022.06.656","article-title":"35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: results from the phase 3 POETYK PSO-1 and PSO-2 trials","volume":"87","author":"Augustin","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/annrheumdis-2022-eular.1377","article-title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials","volume":"81","author":"Warren","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0586|cit586","unstructured":"Efficacy and safety of BMS-986165 versus placebo and active comparator in subjects with psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-001926-25-ES"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0587|cit587","first-page":"65","article-title":"Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and PSO-2 trials","volume":"63","author":"Foley","year":"2022","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub7-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2021-eular.1002","article-title":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 study","volume":"80","author":"Armstrong","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0589|cit589","first-page":"14","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial","volume":"14","author":"Strober","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0590|cit590","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0591|cit591","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0592|cit592","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis https:\/\/clinicaltrials.gov\/show\/nct03611751"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0593|cit593","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis na\u00efve to systemic treatment","volume":"182","author":"Reich","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0594|cit594","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/ddg.15292","article-title":"Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis","volume":"22","author":"Augustin","year":"2024","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0595|cit595","unstructured":"A study of Ixekizumab (LY2439821) in participants with moderate-to-severe plaque psoriasis naive to systemic treatment https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02325219"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0596|cit596","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.19558","article-title":"Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"184","author":"Leutz","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000066425","article-title":"Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study","volume":"205","author":"Tha\u00e7i","year":"2002","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0598|cit598","unstructured":"A randomized, double-blind, placebo-controlled, comparative, prospective, multicentre trial to assess efficacy and safety of apremilast tablets in subjects with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=16164&EncHid=&modid=&compid=%27,%2716164det%27\/CTRI\/2016\/10\/007345"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0599|cit599","unstructured":"Study the efficacy and side effects of subcutaneous v\/s oral methotrexate in the management of moderate to severe psoriasis and palmoplantar psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/10\/028555"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0600|cit600","unstructured":"Regulatory T-cell function in psoriasis vulgaris www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000716"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0601|cit601","unstructured":"A randomised, double blind, placebo controlled efficacy and safety trial of different doses\/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-020168-39-DE"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0602|cit602","unstructured":"The influence of adalimumab on cardiovascular and metabolic risk in psoriasis clinicaltrials.gov\/show\/nct01088165"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0603|cit603","unstructured":"A study to evaluate the effectiveness of Stelara\u2122 (ustekinumab) in the treatment of scalp psoriasis clinicaltrials.gov\/ct2\/show\/NCT01558310"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0604|cit604","unstructured":"Safety and efficacy study of etanercept (Qiangke\u00ae) to treat moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct02701205"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0605|cit605","unstructured":"Multicenter randomized double blind controlled-study to assess the potential of methotrexate versus placebo to improve and maintain response to anti TNF- alpha agents in adult patients with moderate to severe psoriasis clinicaltrials.gov\/show\/nct02829424"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0607|cit607","doi-asserted-by":"publisher","first-page":"111406","DOI":"10.1016\/j.jclinepi.2024.111406","article-title":"Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review","volume":"173","author":"Beytout","year":"2024","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0608|cit608","doi-asserted-by":"crossref","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2019.08.006","article-title":"Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting","volume":"121","author":"Liang","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0610|cit610","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub7-BIB0611|cit611","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jdv.16566","article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database","volume":"35","author":"Grodner","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0612|cit612","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0613|cit613","doi-asserted-by":"crossref","unstructured":"Guelimi R Afach S Bettuzzi T Chaby G Sbidian E Overlapping network meta-analyses on psoriasis systemic treatments: an overview, quantity does not make quality British Journal of Dermatology 2022 187 1 29 41 10.1111\/bjd.20908","DOI":"10.1111\/bjd.20908"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"111411","DOI":"10.1016\/j.jclinepi.2024.111411","article-title":"Funding and conclusions of network meta-analyses on targeted therapies in inflammatory diseases: an overview","volume":"172","author":"Guelimi","year":"2024","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub7-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s13555-021-00602-z","article-title":"Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis","volume":"11","author":"Fahrbach","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0616|cit616","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0617|cit617","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","article-title":"Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatology and Therapy"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub7-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","article-title":"Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis","volume":"12","author":"Blauvelt","year":"2022","journal-title":"Dermatology and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0620|cit620","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/09546634.2020.1747592","article-title":"Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis \u2013 efficacy findings up to week 12","volume":"33","author":"Gottlieb","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0621|cit621","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s12325-022-02065-w","article-title":"Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis","volume":"39","author":"Leonardi","year":"2022","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CM9.0000000000001817","article-title":"Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis","volume":"135","author":"Pan","year":"2021","journal-title":"Chinese Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"308","DOI":"10.5414\/CP203831","article-title":"Relative efficacy and safety of tofacitinib for treating psoriasis: a Bayesian network meta-analysis of randomized controlled trials","volume":"59","author":"Song","year":"2021","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0625|cit625","first-page":"47","article-title":"Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis","volume":"19","author":"Xu","year":"2021","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft (Journal of the German Society of Dermatology : JDDG)"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub7-BIB0626|cit626","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","article-title":"Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year","volume":"33","author":"Yasmeen","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis \u2013 a network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub7-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatology and Therapy"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub7-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/bmjebm-2024-112848","article-title":"Vibration of effects resulting from treatment selection in mixed-treatment comparisons: a multiverse analysis on network meta-analyses of antidepressants in major depressive disorder","volume":"29","author":"Vinatier","year":"2024","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0630|cit630","doi-asserted-by":"crossref","first-page":"f5195","DOI":"10.1136\/bmj.f5195","article-title":"The effects of excluding treatments from network meta-analyses: survey","volume":"347","author":"Mills","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0631|cit631","unstructured":"Dias S Sutton A Welton N NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment https:\/\/www.sheffield.ac.uk\/nice-dsu"},{"key":"10.1002\/14651858.CD011535.pub7-BIB0632|cit632","doi-asserted-by":"crossref","unstructured":"Afach S Le Cleach L Sbidian E Placebo response in moderate-to-severe psoriasis: prevalence meta-analysis of randomised controlled trials Journal of Investigative Dermatology 2023 143 6 1101 4 10.1016\/j.jid.2022.10.024","DOI":"10.1016\/j.jid.2022.10.024"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub7-BIB0633|cit633","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015263","article-title":"Serious adverse events associated with systemic treatments for psoriasis: a network meta-analysis of observational studies and randomized controlled trials","author":"Guelimi","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub7-BIB0634|cit634","first-page":"617","article-title":"Clinical efficacy of ciclosporin in the treatment of psoriasis: multicenter double blind study","volume":"7","author":"Clinical Study Group for Ciclosporin","year":"1991","journal-title":"Rincho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub7-BIB0635|cit635","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:00:52Z","timestamp":1788382852000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011535.pub7"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":635,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011535.pub7","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}